

Patient agreement to systemic anti-cancer therapy (SACT)

DVTd (Daratumumab, Bortezomib, Thalidomide and Dexamethasone)

Hospital/NHS Trust/NHS Board:

Responsible consultant:

Name: _____

Job title: _____

Patient details

Patient's surname/family name:

Patient's first name(s): _____

Date of birth: _____

NHS number: _____
(or other identifier)

Special requirements:
(eg other language/other communication method)

Name of proposed course of treatment (include brief explanation if medical term not clear)

- ☐ Daratumumab, Bortezomib, Thalidomide and Dexamethasone for the treatment of multiple myeloma.
- ☐ Bortezomib is given subcutaneously on days 1, 8, 15 and 22. Daratumumab is given subcutaneously on days 1 and 15 (in cycles 1 and 2, Daratumumab is also given on days 8 and 22). Dexamethasone is taken orally on days 1 and 2, 8 and 9, 15 and 16, 22 and 23. Thalidomide is taken orally each day, continuously.
- ☐ Each treatment cycle lasts for 28 days.
- ☐ Induction treatment is given for 4 cycles. A further 2 cycles of consolidation treatment is available.

Where will I have treatment?

☐ Outpatient ☐ Day unit/case ☐ Inpatient ☐ Other: _____

Statement of health professional

(to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/Trust/NHS board's consent policy)

☒ Tick all relevant boxes

☐ I confirm the patient has capacity to give consent.

☐ I have explained the course of treatment and intended benefit to the patient.

The intended benefits (there are no guarantees about outcome)

☐ Induction – therapy given in the acute stage of the disease, aiming to shrink the tumour before further treatment or stem cell transplant.

Statement of health professional

Patient identifier/label

You may have one or more of the side effects listed

Common side effects:

Affecting more than 10 in every 100 (>10%) people

- ☐ An increased risk of getting an infection from a drop in white blood cells - it is harder to fight infections and you can become very ill.
- ☐ **If you have a severe infection this can be life-threatening. Contact your doctor or hospital straight away if:**
 - **your temperature goes over 37.5°C or over 38°C, depending on the advice given by your chemotherapy team**
 - **you suddenly feel unwell (even with a normal temperature)**
- ☐ **Cancer and Thalidomide can increase your risk of developing a blood clot (thrombosis), causing pain, redness, swelling in an arm or leg, breathlessness, chest pain or stroke. Tell your doctor straight away if you have symptoms. You may be given medication to prevent or treat this.**
- ☐ Daratumumab may cause low levels of protective antibodies in the blood that prevents infection.
- ☐ Tiredness, feeling weak, aches, pain, spasms, cramps, weakness in muscles and joints, build-up of fluid in the hands and feet.
- ☐ Feeling sick (nausea), being sick (vomiting), diarrhoea, constipation, appetite loss.
- ☐ Numbness or tingling in hands and feet, burning sensation, nerve pain, tremor. Tell your doctor if you have persistent pain and find it hard to fasten buttons or do other fiddly tasks, as this can be long term or permanent.
- ☐ Anaemia (due to low red blood cells), bruising and bleeding (due to low platelets).
- ☐ Skin rash.

Occasional side effects:

Affecting between 1-10 in every 100 (1-10%) people

- ☐ Reactions may happen while Daratumumab is being given or shortly after. They are most likely with the first two doses. Symptoms: flu-like symptoms, high or low blood pressure, flushing, shortness of breath, feeling sick or being sick, faster or irregular heartbeat, allergic reactions (severe reactions are less common).
- ☐ Changes in how well the liver works (monitored with blood tests). Less commonly, this may be severe. Tell your doctor if you have yellowing skin or eyes, dark urine, pale stools, pain in the right side of the tummy, feeling or being sick.

Occasional side effects continued:

- ☐ Taste changes, sore mouth and ulcers, indigestion, tummy pain, passing wind, a bleed in the digestive tract, inflammation of the pancreas.
- ☐ Changes in the lungs (inflammation, scarring or build-up of fluid) causing a cough, chest pain, shortness of breath. Tell your doctor if you have symptoms at rest or with gentle activity.
- ☐ A painful, itchy rash on one side of the face or body (shingles), you may be given medication to prevent or treat this.
- ☐ Red, dry, itchy skin, a reaction or pain at the injection site.
- ☐ Hearing loss, cysts in the eyelids, blurred vision, sore, red, gritty eyes (conjunctivitis), dry eye, clouding in the eye (cataract).
- ☐ Increased risk of a second cancer (years later), particularly of the blood. Protect your skin from sunlight. It is important to attend cancer screening, even after treatment.
- ☐ Blood pressure changes which may cause dizziness on standing, irregular heart rhythm which may cause palpitations.
- ☐ Anxiety, feeling sad, disorientation, mood swings, restlessness, agitation, loss of balance, spinning sensation, seizures, loss of co-ordination.
- ☐ Changes in how well the kidneys work, low electrolyte levels, changes in blood sugar levels.

Other risks:

- ☐ **Thalidomide and other anti-cancer medicines damage development of a baby in the womb. It is important not to become pregnant or make someone else pregnant during treatment or for 3 months after. Use effective contraception for 4 weeks before treatment, during treatment, and 3 months after. If you are able to become pregnant, you will have pregnancy tests before each treatment cycle.**
- ☐ Daratumumab can affect tests used to match your blood for blood transfusions. This can last for 6 months after treatment. Tell a doctor or nurse that you are having Daratumumab if you need to have a blood transfusion.
- ☐ Side effects of Dexamethasone include: mood changes, difficulty sleeping, weaker bones and increased risk of a break, muscle weakness, indigestion, increased appetite, high blood sugar levels, skin thinning, bruising, stretch marks, extra hair growth, sweating, eye problems.

Continue to the next page

Statement of health professional

Patient identifier/label

Other risks continued:

- ☐ Bortezomib may cause poor alcohol tolerance. Alcohol may worsen side effects (such as numbness and tingling in the hands and feet).
- ☐ Increased risk of tumour lysis syndrome (when treatment destroys cancer cells too quickly for the kidneys to cope). Rarely, dialysis is needed. You may be prescribed medicines for prevention.
- ☐ Before treatment you might have blood tests to check for viruses (Hepatitis B, Hepatitis C, HIV or more unusual infections). This treatment may weaken your natural defence (immune) system, so infections could worsen or become active again if you've had them before. You may have medicines to prevent or treat infection.
- ☐ Changes in memory, concentration, confusion.
- ☐ Uncommonly: allergic reactions, nervous system effects (headaches, fits, reduced sensations, tremor, vision changes), changes in how the heart works, angina, heart rate changes.
- ☐ Rarely: a serious brain infection (causing face drooping, speech problems, difficulty walking), severe skin reactions (causing sore red patches that blister and peel).
- ☐ Some anti-cancer medicines can damage ovaries and sperm which may lead to infertility and/or early menopause.
- ☐ Complications of treatment can occasionally be life-threatening and may result in death. The risks are different for every individual. Potentially life-threatening complications include those listed on this form, but, other exceedingly rare side effects may also be life-threatening.

Statement of health professional

Patient identifier/label

Any other risks and information:

- ☐ I have discussed the intended benefit and risks of the recommended treatment, and of any available alternative treatments (including no treatment).
- ☐ I have discussed the side effects of the recommended treatment, which could affect the patient straight away or in the future, and that there may be some side effects not listed because they are rare or have not yet been reported. Each patient may experience side effects differently.
- ☐ I have discussed what the treatment is likely to involve (including inpatient/outpatient treatment, timing of the treatment, blood and any additional tests, follow-up appointments etc) and location.
- ☐ I have explained to the patient, that they have the right to stop this treatment at any time and should contact the responsible consultant or team if they wish to do so.
- ☐ I have discussed concerns of particular importance to the patient in regard to treatment (please write details here): _____

Clinical management guideline/Protocol compliant (please tick):

☐ Yes ☐ No ☐ Not available If No please document reason here: _____

The following written information has been provided:

- ☐ Information leaflet for DVTd (Daratumumab, Bortezomib, Thalidomide and Dexamethasone)
- ☐ Thalidomide treatment initiation form
- ☐ 24 hour alert card or SACT advice service contact details and Daratumumab alert card
- ☐ SACT treatment record (cruk.org/treatment-record)
- ☐ Other, please state: _____

Health professional details:

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Statement of interpreter (where appropriate)

Interpreter booking reference (if applicable):

I have interpreted the information above to the patient to the best of my ability and in a way in which I believe they can understand.

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Statement of patient

Patient identifier/label

Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask – we are here to help you. You have the right to change your mind at any time, including after you have signed this form.

☐ I have had enough time to consider my options and make a decision about treatment.

☐ I agree to the course of treatment described on this form.

A witness should sign below if the patient is unable to sign but has indicated their consent. A person with parental responsibility will be asked to sign for young people under the age of 16 years.

Patient's signature: _____

Name (PRINT): _____ Date: _____

Person with parental responsibility/witness' signature: _____

Name (PRINT): _____ Date: _____

Copy accepted by patient: yes / no (please circle)

Confirmation of consent

(health professional to complete when the patient attends for treatment, if the patient has signed the form in advance)

On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of treatment/procedures to go ahead.

Signed: _____

Date: _____

Name (PRINT): _____

Job title: _____

Important notes: (tick if applicable)

☐ See also advance decision to refuse treatment

☐ Patient has withdrawn consent
(ask patient to sign and date here)

Signed: _____

Date: _____

Further information for patients

Contact details (if patient wishes to discuss options later):

Contact your hospital team if you have any questions about cancer and its treatment.

Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone 0808 800 4040, Monday to Friday, 9am to 5pm. Alternatively visit cruk.org for more information.

These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT.

The project is supported by Cancer Research UK.
This does not mean you are taking part in a clinical trial.



Guidance for health professionals

(to be read in conjunction with the hospital's consent policy)

Patient identifier/label

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or
- communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. If patients make clear they have particular concerns about certain kinds of risk, you should ensure that they are informed about these risks, even if very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

NHS Scotland

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scottish legal framework.

References

1. Summary of Product Characteristics for individual drugs: medicines.org.uk/emc
1. Cancer Research UK: cruk.org/about-cancer/treatment/drugs
2. Macmillan Cancer Support: macmillan.org.uk/cancer-information-and-support/treatments-and-drugs
3. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent form